Calendar
2015 European Cancer Congress
September 25 – 29, 2015
Vienna, Austria
The European Cancer Congress (ECC 2015) is a biennial
congress that combines the efforts of the most important European oncology professionals with the aim of
improving the prevention, diagnosis, treatment, and
care of cancer patients.
Improving MDS Outcomes from Diagnosis
to Treatment: A Multidisciplinary Approach
Co-hosted by ASH, the American Society for Clinical Pathology, and the France Foundation, these complimentary CME summits on MDS are designed with the goal
of improving performance diagnosis and treatment of
MDS patients. There are two remaining workshops being
offered this year:
American Society for Radiation Oncology
Annual Meeting
The 53rd Annual Meeting of the Japan
Society of Clinical Oncology
This year, ASTRO invites more than 11,000 attendees
to its 57th Annual Meeting to discuss the theme of
“Technology Meets Patient Care.”
Japan’s largest multidisciplinary academic society of
clinical oncology will hold its annual meeting as an
open discussion of the latest advances in current cancer
treatment.
October 18 – 21, 2015
San Antonio, TX
October 24 – 26, 2015
Kyoto, Japan
October 9, 2015
New York, NY
October 16, 2015
Tampa, FL
TASIGNA® (nilotinib) Capsules for oral use
Initial U.S. Approval: 2007
BRIEF SUMMARY: Please see package insert for full prescribing
information.
WARNING: QT PROLONGATION AND SUDDEN DEATHS
• Tasigna prolongs the QT interval. Prior to Tasigna administration and
periodically, monitor for hypokalemia or hypomagnesemia and correct
deficiencies (5.2). Obtain ECGs to monitor the QTc at baseline, seven
days after initiation, and periodically thereafter, and following any
dose adjustments (5.2, 5.3, 5.7, 5.15).
• Sudden deaths have been reported in patients receiving nilotinib (5.3).
Do not administer Tasigna to patients with hypokalemia, hypomagnesemia, or long QT syndrome (4, 5.2).
• Avoid use of concomitant drugs known to prolong the QT interval and
strong CYP3A4 inhibitors (5.8).
• Avoid food 2 hours before and 1 hour after taking the dose (5.9).
1 INDICATIONS AND USAGE
1.1 Newly Diagnosed Ph+ CML-CP
Tasigna (nilotinib) is indicated for the treatment of adult patients with
newly diagnosed Philadelphia chromosome positive chronic myeloid
leukemia (Ph+ CML) in chronic phase. The effectiveness of Tasigna is
based on major molecular response and cytogenetic response rates [see
Clinical Studies (14.1) in the full prescribing information].
1.2 Resistant or Intolerant Ph+ CML-CP and CML-AP
Tasigna is indicated for the treatment of chronic phase and accelerated
phase Philadelphia chromosome positive chronic myelogenous leukemia
(Ph+ CML) in adult patients resistant or intolerant to prior therapy that
included imatinib. The effectiveness of Tasigna is based on hematologic
and cytogenetic response rates [see Clinical Studies (14.2) in the full
prescribing information].
4 CONTRAINDICATIONS
Do not use in patients with hypokalemia, hypomagnesemia, or long
QT syndrome [see Boxed Warning].
5 WARNINGS AND PRECAUTIONS
5.1 Myelosuppression
Treatment with Tasigna can cause Grade 3/4 thrombocytopenia, neutropenia and anemia. Perform complete blood counts every 2 weeks for the first
2 months and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and usually managed by withholding
Tasigna temporarily or dose reduction [see Dosage and Administration
(2.2) in the full prescribing information].
5.2 QT Pro